Nintedanib in children and adolescents with fibrosing interstitial lung disease: the InPedILD* trial**

Autoren M. Griese,R. Deterding, L. Young,E. DeBoer,D. Warburton, S. Cunningham,N. Schwerk,K. Flaherty, K. Brown,M. Dumistracel,E. Erhardt, J. Bertulis, M. Gahlemann,S. Stowasser

12.04 - Rare ILD/DPLD（2023）

引用 0|浏览4

暂无评分

摘要

Background Nintedanib is approved for the treatment of pulmonary fibrosis in adults. There are no licensed treatments for fibrosing ILD in children and adolescents ([Abb. 1]).

查看译文

关键词

interstitial lung disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要